Movement Alert｜Sino Biopharmaceutical Rises 3.21% in Regular Trading, Defu Combo Phase III Data Shows Head-to-Head Win in First-Line Non-Squamous NSCLC at ASCO

Market Focus06-01

On June 1, Sino Biopharmaceutical rose 3.21% in regular trading, trading at 5.04 HKD/share, with trading volume of approximately 92.31 million HKD.

On the news front, the company's proprietary Defu Combination (bemosubaizumab + anlotinib) was presented as a Late-Breaking Abstract at the ASCO Annual Meeting, disclosing Phase III clinical data for first-line treatment of non-squamous non-small cell lung cancer (NSCLC). The trial demonstrated head-to-head superiority over tislelizumab plus standard chemotherapy, making it the first globally to achieve a positive result in a Phase III study challenging PD-1 inhibitor plus chemotherapy in first-line non-squamous NSCLC. Additionally, the company simultaneously presented Phase II data for its CLDN18.2 ADC (LM-302) in first-line gastric cancer and first-in-human Phase I data for its EGFR/c-Met ADC (TQB6411), reflecting intensive pipeline catalysts. TQB6411 demonstrated favorable safety profiles at effective doses with low hematological toxicity, representing one of the first EGFR/c-Met ADCs globally to report clinical data.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108202020?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 09:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108202020","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Sino Biopharmaceutical Rises 3.21% in Regular Trading, Defu Combo Phase III Data Shows Head-to-Head Win in First-Line Non-Squamous NSCLC at ASCO","media":"Market Focus","content":"<p><p>On June 1, Sino Biopharmaceutical rose 3.21% in regular trading, trading at 5.04 HKD/share, with trading volume of approximately 92.31 million HKD.</p><p>On the news front, the company's proprietary Defu Combination (bemosubaizumab + anlotinib) was presented as a Late-Breaking Abstract at the ASCO Annual Meeting, disclosing Phase III clinical data for first-line treatment of non-squamous non-small cell lung cancer (NSCLC). The trial demonstrated head-to-head superiority over tislelizumab plus standard chemotherapy, making it the first globally to achieve a positive result in a Phase III study challenging PD-1 inhibitor plus chemotherapy in first-line non-squamous NSCLC. Additionally, the company simultaneously presented Phase II data for its CLDN18.2 ADC (LM-302) in first-line gastric cancer and first-in-human Phase I data for its EGFR/c-Met ADC (TQB6411), reflecting intensive pipeline catalysts. TQB6411 demonstrated favorable safety profiles at effective doses with low hematological toxicity, representing one of the first EGFR/c-Met ADCs globally to report clinical data.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Sino Biopharmaceutical Rises 3.21% in Regular Trading, Defu Combo Phase III Data Shows Head-to-Head Win in First-Line Non-Squamous NSCLC at ASCO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Sino Biopharmaceutical Rises 3.21% in Regular Trading, Defu Combo Phase III Data Shows Head-to-Head Win in First-Line Non-Squamous NSCLC at ASCO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-01 09:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 1, Sino Biopharmaceutical rose 3.21% in regular trading, trading at 5.04 HKD/share, with trading volume of approximately 92.31 million HKD.</p><p>On the news front, the company's proprietary Defu Combination (bemosubaizumab + anlotinib) was presented as a Late-Breaking Abstract at the ASCO Annual Meeting, disclosing Phase III clinical data for first-line treatment of non-squamous non-small cell lung cancer (NSCLC). The trial demonstrated head-to-head superiority over tislelizumab plus standard chemotherapy, making it the first globally to achieve a positive result in a Phase III study challenging PD-1 inhibitor plus chemotherapy in first-line non-squamous NSCLC. Additionally, the company simultaneously presented Phase II data for its CLDN18.2 ADC (LM-302) in first-line gastric cancer and first-in-human Phase I data for its EGFR/c-Met ADC (TQB6411), reflecting intensive pipeline catalysts. TQB6411 demonstrated favorable safety profiles at effective doses with low hematological toxicity, representing one of the first EGFR/c-Met ADCs globally to report clinical data.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1108202020","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108202020","pubTimestamp":1780278981,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 1, Sino Biopharmaceutical rose 3.21% in regular trading, trading at 5.04 HKD/share, with trading volume of approximately 92.31 million HKD.On the news front, the company's proprietary Defu...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"动静快讯|中国生物制药常规交易涨3.21%，得福组合III期数据显示在ASCO一线非鳞状非小细胞肺癌中正面胜出","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"On June 1, Sino Biopharmaceutical rose 3.21% in regular trading, trading at 5.04 HKD/share, with trading volume of approximately 92.31 million HKD.On the news front, the company's proprietary Defu Combination (bemosubaizumab + anlotinib) was presented as a Late-Breaking Abstract at the ASCO Annual Meeting, disclosing Phase III clinical data for first-line treatment of non-squamous non-small cell lung cancer (NSCLC). The trial demonstrated head-to-head superiority over tislelizumab plus standard chemotherapy, making it the first globally to achieve a positive result in a Phase III study challenging PD-1 inhibitor plus chemotherapy in first-line non-squamous NSCLC. Additionally, the company simultaneously presented Phase II data for its CLDN18.2 ADC (LM-302) in first-line gastric cancer and first-in-human Phase I data for its EGFR/c-Met ADC (TQB6411), reflecting intensive pipeline catalysts. TQB6411 demonstrated favorable safety profiles at effective doses with low hematological toxicity, representing one of the first EGFR/c-Met ADCs globally to report clinical data.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108202020","isCrawlerRequest":true}